JP2017538769A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017538769A5 JP2017538769A5 JP2017533416A JP2017533416A JP2017538769A5 JP 2017538769 A5 JP2017538769 A5 JP 2017538769A5 JP 2017533416 A JP2017533416 A JP 2017533416A JP 2017533416 A JP2017533416 A JP 2017533416A JP 2017538769 A5 JP2017538769 A5 JP 2017538769A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- salt
- pharmaceutically acceptable
- solvate
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000003839 salts Chemical class 0.000 claims 28
- 150000001875 compounds Chemical class 0.000 claims 22
- 239000012453 solvate Substances 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- QEUAUMWHNLVMDZ-HXUWFJFHSA-N 6-(5-fluoroquinolin-7-yl)-3-[(3R)-3-methyl-2-oxopiperidin-3-yl]-1H-pyridin-2-one Chemical compound FC1=C2C=CC=NC2=CC(=C1)C1=CC=C(C(N1)=O)[C@@]1(C(NCCC1)=O)C QEUAUMWHNLVMDZ-HXUWFJFHSA-N 0.000 claims 2
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 claims 1
- OJVNYQOKTZLPPX-OAQYLSRUSA-N 3-[(3R)-3-methyl-2-oxopiperidin-3-yl]-6-(5-methylquinolin-3-yl)-1H-pyridin-2-one Chemical compound C[C@]1(C(NCCC1)=O)C=1C(NC(=CC=1)C=1C=NC2=CC=CC(=C2C=1)C)=O OJVNYQOKTZLPPX-OAQYLSRUSA-N 0.000 claims 1
- URFCQPHIMBZYON-OAQYLSRUSA-N 3-[(3R)-3-methyl-2-oxopiperidin-3-yl]-6-(5-methylquinolin-7-yl)-1H-pyridin-2-one Chemical compound C[C@]1(C(NCCC1)=O)C=1C(NC(=CC=1)C1=CC(=C2C=CC=NC2=C1)C)=O URFCQPHIMBZYON-OAQYLSRUSA-N 0.000 claims 1
- NYMPHOZUBJYHBQ-HXUWFJFHSA-N 3-[(3R)-3-methyl-2-oxopyrrolidin-3-yl]-6-(5-methylquinolin-3-yl)-1H-pyridin-2-one Chemical compound C[C@]1(C(NCC1)=O)C=1C(NC(=CC=1)C=1C=NC2=CC=CC(=C2C=1)C)=O NYMPHOZUBJYHBQ-HXUWFJFHSA-N 0.000 claims 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- ALGSMAYBBGCDSR-HXUWFJFHSA-N 6-(5-chloroquinolin-7-yl)-3-[(3R)-3-methyl-2-oxopiperidin-3-yl]-1H-pyridin-2-one Chemical compound ClC1=C2C=CC=NC2=CC(=C1)C1=CC=C(C(N1)=O)[C@@]1(C(NCCC1)=O)C ALGSMAYBBGCDSR-HXUWFJFHSA-N 0.000 claims 1
- JXKXDDNPECXKSM-HSZRJFAPSA-N 6-(5-cyclopropylquinolin-7-yl)-3-[(3R)-3-methyl-2-oxopiperidin-3-yl]-1H-pyridin-2-one Chemical compound C1(CC1)C1=C2C=CC=NC2=CC(=C1)C1=CC=C(C(N1)=O)[C@@]1(C(NCCC1)=O)C JXKXDDNPECXKSM-HSZRJFAPSA-N 0.000 claims 1
- KPRFPENKXRBQRF-JOCHJYFZSA-N 6-(5-ethylquinolin-7-yl)-3-[(3R)-3-methyl-2-oxopiperidin-3-yl]-1H-pyridin-2-one Chemical compound C(C)C1=C2C=CC=NC2=CC(=C1)C1=CC=C(C(N1)=O)[C@@]1(C(NCCC1)=O)C KPRFPENKXRBQRF-JOCHJYFZSA-N 0.000 claims 1
- ICRVRXNPWUOCMP-IVAFLUGOSA-N CCc1cc(cc2ncccc12)C1=NC(=O)C(C=C1)[C@@]1(C)CCCNC1=O Chemical compound CCc1cc(cc2ncccc12)C1=NC(=O)C(C=C1)[C@@]1(C)CCCNC1=O ICRVRXNPWUOCMP-IVAFLUGOSA-N 0.000 claims 1
- ZTBLZTHRYZXYNZ-WBPHRXDCSA-N C[C@@]1(CCCNC1=O)C1C=CC(=NC1=O)c1cc(C2CC2)c2cccnc2c1 Chemical compound C[C@@]1(CCCNC1=O)C1C=CC(=NC1=O)c1cc(C2CC2)c2cccnc2c1 ZTBLZTHRYZXYNZ-WBPHRXDCSA-N 0.000 claims 1
- SGMZEERLWJABMZ-YBMSBYLISA-N C[C@@]1(CCCNC1=O)C1C=CC(=NC1=O)c1cc(Cl)c2cccnc2c1 Chemical compound C[C@@]1(CCCNC1=O)C1C=CC(=NC1=O)c1cc(Cl)c2cccnc2c1 SGMZEERLWJABMZ-YBMSBYLISA-N 0.000 claims 1
- SSQLJNRCSCKPFA-MYKUNDNFSA-N Cc1cc(cc2ncccc12)C1CCC(C(=O)N1)[C@@]1(C)CCCNC1=O Chemical compound Cc1cc(cc2ncccc12)C1CCC(C(=O)N1)[C@@]1(C)CCCNC1=O SSQLJNRCSCKPFA-MYKUNDNFSA-N 0.000 claims 1
- ZUCVEFCHDRKBHT-MYKUNDNFSA-N Cc1cccc2ncc(cc12)C1CCC(C(=O)N1)[C@@]1(C)CCCNC1=O Chemical compound Cc1cccc2ncc(cc12)C1CCC(C(=O)N1)[C@@]1(C)CCCNC1=O ZUCVEFCHDRKBHT-MYKUNDNFSA-N 0.000 claims 1
- RXTUYFXTGPOYIV-ALLBUHFWSA-N Cc1cccc2ncc(cc12)C1CCC(C(=O)N1)[C@@]1(C)CCNC1=O Chemical compound Cc1cccc2ncc(cc12)C1CCC(C(=O)N1)[C@@]1(C)CCNC1=O RXTUYFXTGPOYIV-ALLBUHFWSA-N 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 150000004682 monohydrates Chemical class 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000007614 solvation Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462095337P | 2014-12-22 | 2014-12-22 | |
| US62/095,337 | 2014-12-22 | ||
| US201562259528P | 2015-11-24 | 2015-11-24 | |
| US62/259,528 | 2015-11-24 | ||
| PCT/IB2015/059548 WO2016103097A1 (en) | 2014-12-22 | 2015-12-11 | Antagonists of prostaglandin ep3 receptor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017538769A JP2017538769A (ja) | 2017-12-28 |
| JP2017538769A5 true JP2017538769A5 (enExample) | 2019-01-24 |
Family
ID=55077554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017533416A Withdrawn JP2017538769A (ja) | 2014-12-22 | 2015-12-11 | プロスタグランジンｅｐ３受容体の拮抗薬 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9738626B2 (enExample) |
| EP (1) | EP3237401B1 (enExample) |
| JP (1) | JP2017538769A (enExample) |
| CA (1) | CA2915470A1 (enExample) |
| TW (1) | TW201632513A (enExample) |
| UY (1) | UY36455A (enExample) |
| WO (1) | WO2016103097A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10590083B2 (en) | 2017-08-10 | 2020-03-17 | Janssen Pharmaceutica Nv | Pyridin-2-one derivatives of formula (I) useful as EP3 receptor antagonists |
| US10399944B2 (en) | 2017-08-10 | 2019-09-03 | Janssen Pharmaceutica Nv | Pyridin-2-one derivatives of formula (III) useful as EP3 receptor antagonists |
| US10336701B2 (en) | 2017-08-10 | 2019-07-02 | Janssen Pharmaceutica Nv | Pyridin-2-one derivatives of formula (II) useful as EP3 receptor antagonists |
| BR112020021612A2 (pt) | 2018-05-17 | 2021-01-26 | Bayer Aktiengesellschaft | derivados substituídos de di-hidropirazolo pirazina carboxamida |
| WO2021094210A1 (en) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted pyrazine carboxamide derivatives as prostaglandin ep3 receptor antagonists |
| WO2021094209A1 (en) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted pyrrolo triazine carboxamide derivatives as prostaglandin ep3 receptor antagonists |
| WO2021094208A1 (en) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted imidazo pyrimidine ep3 antagonists |
| WO2022215072A2 (en) | 2021-04-07 | 2022-10-13 | Hadasit Medical Research Services & Development Ltd. | Therapeutic modalities for inhibiting pancreatic beta cell impairment and treating diabetes |
| CN116106398A (zh) * | 2022-08-03 | 2023-05-12 | 南方医科大学珠江医院 | 用于诊断ckd的标志物 |
| AU2024235437A1 (en) * | 2023-03-13 | 2025-09-25 | Ono Pharmaceutical Co., Ltd. | Tricyclic compound |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4219483A (en) | 1978-09-11 | 1980-08-26 | Pfizer Inc. | 4-Pyrone prostaglandin antagonists |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| PT1094816E (pt) | 1998-07-06 | 2009-03-10 | Bristol Myers Squibb Co | Sulfonamidas bifenílicas duplamente antagonistas receptores de angiotensina e endotelina |
| MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
| GEP20053710B (en) | 2001-02-28 | 2005-12-26 | Merck & Co Inc | Acylated Piperidine Derivatives as Melanocortin-4 Receptor Agonists |
| US20030195205A1 (en) | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
| NZ534582A (en) | 2002-02-27 | 2006-03-31 | Pfizer Prod Inc | ACC inhibitors |
| DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
| DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
| US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
| EP1753748B1 (en) | 2004-05-12 | 2009-07-29 | Pfizer Products Inc. | Proline derivatives and their use as dipeptidyl peptidase iv inhibitors |
| EA010888B1 (ru) | 2004-05-25 | 2008-12-30 | Пфайзер Продактс, Инк. | Тетраазабензо[е]азуленовые производные и их аналоги |
| CA2577748A1 (en) | 2004-08-26 | 2006-03-02 | Actelion Pharmaceuticals Ltd | 2-sulfanyl-benzoimidazol-1-yl-acetic acid derivatives as crth2 antagonists |
| PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
| WO2007027630A2 (en) | 2005-08-30 | 2007-03-08 | Smithkline Beecham Corporation | Genes associated with type ii diabetes mellitus |
| EP2463283B1 (en) | 2006-04-20 | 2014-06-11 | Pfizer Products Inc. | Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases |
| EP2097420B1 (en) | 2006-11-29 | 2012-04-04 | Pfizer Products Inc. | Spiroketone inhibitors of acetyl-coa carboxylase |
| MX2009011998A (es) | 2007-05-10 | 2009-11-19 | Pfizer Ltd | Derivados de azetidina y su uso como antagonistas de prostaglandina e2. |
| MX2009011830A (es) | 2007-05-11 | 2009-11-13 | Pfizer | Compuestos amino-heterociclicos. |
| US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
| WO2009144554A1 (en) | 2008-05-28 | 2009-12-03 | Pfizer, Inc. | Pyrazolospiroketone acetyl-c0a carboxylase inhibitors |
| CA2724603A1 (en) | 2008-05-28 | 2009-12-03 | Pfizer Inc. | Pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| EP2318370A1 (en) | 2008-07-29 | 2011-05-11 | Pfizer Inc. | Fluorinated heteroaryls |
| MX2011002166A (es) | 2008-08-28 | 2011-04-07 | Pfizer | Derivados de dioxa-biciclo[3.2.1]octano-2,3,1-triol. |
| TW201038580A (en) | 2009-02-02 | 2010-11-01 | Pfizer | 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives |
| ES2427279T3 (es) | 2009-03-11 | 2013-10-29 | Pfizer Inc. | Derivados de benzofuranilo usados como inhibidores de glucocinasa |
| EP2406230A1 (en) | 2009-03-11 | 2012-01-18 | Pfizer Inc. | Substituted indazole amides and their use as glucokinase activators |
| WO2010106457A2 (en) | 2009-03-20 | 2010-09-23 | Pfizer Inc. | 3-oxa-7-azabicyclo[3.3.1]nonanes |
| JP2012526097A (ja) | 2009-05-08 | 2012-10-25 | ファイザー・インク | Ｇｐｒ１１９調節因子 |
| JP2012526096A (ja) | 2009-05-08 | 2012-10-25 | ファイザー・インク | Ｇｐｒ１１９調節因子 |
| KR20120061063A (ko) | 2009-06-05 | 2012-06-12 | 화이자 인코포레이티드 | Ｇｐｒ 119 조절제로서의 ｌ-(피페리딘-4-일)-피라졸 유도체 |
| WO2011005611A1 (en) | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Neuromedin u receptor agonists and uses thereof |
| AP2013007070A0 (en) | 2011-02-23 | 2013-08-31 | Pfizer | Imidazo[5,1-f][1,2,4] triazines for the treatment of neurological disorders |
| EP2718295A1 (en) | 2011-06-07 | 2014-04-16 | Pfizer Inc | Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors |
| JP6348582B2 (ja) | 2013-10-09 | 2018-06-27 | ファイザー・インク | プロスタグランジンｅｐ３受容体の拮抗薬 |
-
2015
- 2015-12-11 EP EP15821169.8A patent/EP3237401B1/en not_active Not-in-force
- 2015-12-11 JP JP2017533416A patent/JP2017538769A/ja not_active Withdrawn
- 2015-12-11 WO PCT/IB2015/059548 patent/WO2016103097A1/en not_active Ceased
- 2015-12-16 US US14/970,930 patent/US9738626B2/en not_active Expired - Fee Related
- 2015-12-17 TW TW104142513A patent/TW201632513A/zh unknown
- 2015-12-17 CA CA2915470A patent/CA2915470A1/en not_active Abandoned
- 2015-12-18 UY UY0001036455A patent/UY36455A/es not_active Application Discontinuation